Crossmark

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

Crossref DOI link: https://doi.org/10.1007/s00280-015-2846-0

Published Online: 2015-08-20

Published Print: 2015-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Venugopal, B.

Awada, A.

Evans, T. R. J.

Dueland, S.

Hendlisz, A.

Rasch, W.

Hernes, K.

Hagen, S.

Aamdal, S.
License Information

Text and Data Mining valid from 2015-08-20